Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open in green
Fri, 25 Jan 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Japan (up 2.3%) and Indonesia (up 0.2%) trading firm. However, markets in Hong Kong (down 0.4%) and South Korea (down 1.3%) are facing selling pressure. The Indian equity market indices have opened the day on a firm note. Stocks in the technology and FMCG space have opened on a positive note. However, realty and oil and gas stocks are trading in the red.

The Sensex today is up by around 50 points (0.3%), while the NSE-Nifty has opened on a flat note. However, the mid cap and small cap stocks have opened in the red with the BSE Mid Cap and BSE Small Cap indices down by 0.1% each. The rupee is trading at Rs 53.73 to the US dollar.

Auto stocks have opened the day on a mixed note with Ashok Leyland Ltd and Mahindra & Mahindra trading in the red. However, Tata Motors Ltd and Maruti Suzuki Ltd have opened on a positive note. The commercial vehicle manufacturer Ashok Leyland Ltd has announced its results for the third quarter of financial year 2013 (3QFY13).The company has reported a revenue decline of 18 % on a year on year (YoY) basis during the quarter. The sales volumes for the quarter declined by 2.2% YoY. As per the management, the quarter was an extremely challenging one for the company. This was against the backdrop of a sluggish economy and weak macro-economic indicators. The net income during the quarter was up by 10.4% YoY boosted by an exceptional gain of Rs 1.6 bn. The exceptional gains were on account of partial sales of non current investments. On a normalized basis, the company has posted a loss of Rs 838 m, from ordinary activities after finance costs. This compares to a profit of around Rs 720 m for the same period last year.

Indian Pharma stocks have opened the mainly in the red with Orchid Chemicals Ltd and Biocon Ltd leading the losses. The biotech major Biocon Ltd has announced its results for the third quarter of financial year 2013 (3QFY13). The growth in the topline came at 23% YoY for the quarter.The sales from its biopharmaceuticals business grew 20 % and those from contract research rose 34 % YoY for the quarter.The company has reported a 9% YoY growth in the net profits. The margins were compressed because of higher expenses that offset the growth in the total sales. The biopharmaceutical income includes licensing development fees and licensing income. Going forward the company aims to have higher contribution from Biosimilars, Research Services and Branded Formulations to the overall revenue.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.